SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Cubist Pharmaceuticals to Present at March 2010 Investor Conferences
[February 17, 2010]

Cubist Pharmaceuticals to Present at March 2010 Investor Conferences


LEXINGTON, Mass. --(Business Wire)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that David McGirr, Cubist's SVP and CFO, will participate on a panel Building on Success Tuesday, March 2nd, 2010, at 2:35 p.m. ET, at the RBC Capital Markets Healthcare Conference at the New York Palace Hotel in New York City. This is an audio-only webcast.



Cubist also announced that Michael Bonney, President and CEO of Cubist, will present on Monday March 8th, 2010, at 3:15 p.m. ET, at the Cowen and Company 30th Annual Health Care Conference being held at The Boston Marriott Copley Place in Boston. There will be a full webcast with slides that will include discussion of the company's business activities, financial outlook, and current news.

Both of the presentations are accessible through Cubist's website at www.cubist.com in the Investor Relations Conference Calendar section and will be available there for a period of 30 days after the presentations.


About Cubist Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. Cubist also promotes MERREM® I.V. (meropenem for injection) in the U.S. under an agreement with AstraZeneca. The Cubist clinical product pipeline currently consists of ecallantide, a recombinant human protein being developed for the reduction of blood loss during cardiac surgery for which we currently are analyzing Phase 2 data; a Phase 2 program, added with Cubist's acquisition of Calixa Therapeutics Inc. in December 2009, focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms; a program for the treatment of CDAD (Clostridium difficile-associated diarrhea), now entering Phase 2; and a Phase 1 program intended to address the unmet medical need for a treatment for serious infections caused by MDR Gram-negative pathogens. Cubist is also working on several pre-clinical programs, which would address areas of significant medical needs. These include an anti-infective program for the treatment of respiratory syncytial virus (RSV) in children, therapies to treat various serious bacterial infections, and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist's web site at www.cubist.com.

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies.

[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2019 Technology Marketing Corporation. All rights reserved | Privacy Policy